Healthcare spending for the Medicaid expansion population increased steadily over time for beneficiaries who remained enrolled in Medicaid, according to a new analysis from Avalere Health. The analysis also found that spending for prescription drugs increased over the study period, with pharmacy costs (excluding prescription drug claims for hepatitis C treatments) almost doubling over the 2.5-year time period during which the cohort was tracked
Healthcare spending for the Medicaid expansion population increased steadily over time for beneficiaries who remained enrolled in Medicaid, according to a new analysis from Avalere Health. The analysis also found that spending for prescription drugs increased over the study period, with pharmacy costs (excluding prescription drug claims for hepatitis C treatments) almost doubling over the 2.5-year time period during which the cohort was tracked—a likely indication that the previously uninsured population may have had previously untreated conditions, and that gaining access to health insurance helped to provide needed care to these enrollees. The analysis concludes that utilization and costs among Medicaid expansion enrollees will continue to increase, particularly for non-acute-care services, the longer members remain covered.
“Contrary to some expectations that Medicaid expansion enrollees would be relatively healthy, beneficiaries who have remained on the program have increasing healthcare needs, likely due to previously unidentified or untreated conditions,” said report coauthor Caroline Pearson, senior vice president at Avalere.
Across plans, states, and enrollment groups, healthier, younger, lower-cost enrollees appear more likely to drop their enrollment in Medicaid after a shorter period of time, the report found: about half of enrollees dropped coverage within 18 months. There are many factors that could be involved in disenrollment from a Medicaid managed care organization (MCO) plan: enrollees could gain access to employer-sponsored insurance, their income could increase and make them ineligible for Medicaid, or individuals could fail to meet a state’s administrative requirement for eligibility redeterminations.
Avalere’s analysis was performed on claims data from January 2014 through December 2016 from 3 Medicaid MCOs offering coverage in states that expanded Medicaid on January 1, 2014 after the Affordable Care Act (ACA) provided states with the option of extending Medicaid eligibility. Many of these new enrollees were previously uninsured.
The analysis found:
Avalere’s report, “Profile of the Medicaid Expansion Population: Demographics, Enrollment, and Utilization,” was funded by the Anthem Public Policy Institute.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.